Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech, Inc. (OTC: NKGN) is a clinical-stage biotechnology company headquartered in Santa Ana, California, focused on autologous and allogeneic natural killer (NK) cell therapeutics. The NKGN news feed highlights company announcements, scientific presentations, regulatory updates, and corporate developments that shape its NK cell therapy programs.
Readers can find detailed coverage of NKGen’s work on troculeucel, a patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate and the International Nonproprietary Name (INN) for SNK01. News items include presentations on troculeucel’s mechanism of action and biomarker data in Alzheimer’s disease, as well as updates on its evaluation across multiple neurodegenerative diseases through clinical trials and an FDA Expanded Access Program authorization.
The news stream also features information on NKGen’s allogeneic NK cell therapy, SNK02, in solid tumors, including scientific and early clinical findings shared at immuno-oncology conferences. Corporate news covers NKGen’s acquisition of a majority equity stake in NKGen Biotech Korea Co., Ltd. (formerly NKMax Co., Ltd.), governance developments at NKGen Korea, and strategic partnerships such as its collaboration with HekaBio in Japan to advance troculeucel under Japan’s regenerative medicine framework.
In addition, NKGen issues updates on its trading status on the OTC Expert Market, clarifying quotation practices and reporting steps taken to address reporting obligations. Investors and observers can use the NKGN news page to follow how NKGen communicates progress in its NK cell therapy pipeline, regional collaborations, manufacturing and intellectual property consolidation, and interactions with regulators and capital providers.
NKGen Biotech (OTC: NKGN) appointed Bruce L. Miller, M.D. to its Scientific Advisory Board on January 22, 2026. Dr. Miller is a leading expert in Alzheimer’s disease, frontotemporal dementia (FTD), and neurocognitive disorders and directs the Edward and Pearl Fein Memory and Aging Center at UCSF.
The company said Dr. Miller will advise clinical and scientific priorities as NKGen advances its Phase 2 trial of autologous NK cell therapy troculeucel in moderate Alzheimer’s disease and explore troculeucel use in FTD after early expanded-access signals.
NKGen Biotech (OTC: NKGN) announced board changes at its majority-owned Korean affiliate NKGen Korea following a shareholder-approved name change on November 21, 2025. NKGen Korea disclosed KOSDAQ appointments of Hanhan Xu, Xuan Zhang, and Dr. June H. Lee to three-year terms, and earlier appointed Dr. Angie You on August 14, 2025 to a one-year term. Leadership backgrounds span scientific development, operations, finance, and venture roles across Asia and the U.S.
The company said it supports the appointments as majority shareholder and expects the new directors to aid NKGen Korea as it emerges from rehabilitation and advances NK cell therapeutic development and commercialization in the Asia-Pacific region.
NKGen Biotech (OTC: NKGN) clarified that recent $0.00 price displays on some financial sites reflect quote dissemination limits on the OTC Expert Market, not the company’s underlying value. Quotations were moved to the OTC Expert Market on or about July 17, 2025 after the company failed to remain current in Exchange Act filings. The company confirmed its common stock remains listed and tradable, but public price quotes and volume are restricted to broker‑dealers and institutions. NKGen filed its Form 10‑K on October 8, 2025 and is working to file Form 10‑Qs for the quarters ended Mar 31, Jun 30, and Sep 30, 2025 to regain compliance and restore public market data access.
NKGen Biotech (OTC:NKGN) will present at the XXVII World Congress of Neurology in Seoul, South Korea on October 12–15, 2025. CEO Paul Y. Song, M.D., will deliver a presentation on troculeucel, an investigational autologous enhanced natural killer (NK) cell therapy for moderate/advanced Alzheimer’s disease.
The talk, titled "Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Moderate/Advanced Alzheimer’s Disease. Scientific Rationale with Preliminary Clinical and Biomarker Results," is scheduled for October 15, 2025 at 11:50 AM KST in Conference Room North 201 during the Free Paper – Ataxia and Cerebellar Disorders & Dementia session. A copy of the presentation will be posted under the company’s Scientific Publications page after the event.
NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases.
The presentation will take place at the Sino-Singapore Guangzhou Knowledge City International Convention Center on September 25, 2025, at 3:20 PM CST. The forum will host over 1,200 experts and 90 speakers, focusing on cell and gene therapy, RNA therapeutics, and stem cell research.
NKGen Biotech (OTC: NKGN) has successfully completed the acquisition of a 65% controlling stake in NKMax Co., Ltd. for $16.9 million. The strategic transaction, funded by AlpineBrook Capital GP 1 Limited and CEO Dr. Paul Y. Song, transforms NKGen into a fully integrated cell therapy company with complete control over global manufacturing infrastructure and intellectual property assets.
The acquisition marks a significant turnaround for NKGen, which faced challenges after NKMax's bankruptcy in 2024 and its own delisting from Nasdaq. The deal secures NKMax's operations through 2026 and positions NKGen to advance its lead therapeutic candidate, troculeucel, which has received FDA fast track designation and shown promising results in over 90% of Alzheimer's patients treated to date.
NKGen Biotech (OTC:NKGN), a clinical-stage biotech company, will present at the 13th Annual Immuno-Oncology Summit in Philadelphia from August 11-13, 2025. CEO Paul Y. Song will discuss their allogeneic NK cell therapy, SNK02, which uniquely treats solid tumors without requiring lymphodepletion.
The presentation, scheduled for August 13, 2025, at 2:50 PM ET, will focus on NK cells' role in fighting cancer and showcase scientific data and early clinical findings. SNK02 represents a potential advancement in cancer treatment by avoiding the immunologic compromises typically associated with traditional allogeneic therapies.
NKGen Biotech (OTC:NKGN) presented groundbreaking Phase 1 data for troculeucel, their innovative NK cell therapy for Alzheimer's disease, at AAIC 2025. The therapy demonstrated remarkable efficacy with 92% of patients (12 out of 13) showing stable or improved cognitive function after three months.
Key findings revealed that troculeucel can cross the blood-brain barrier and exhibits multiple mechanisms of action, including reduction of neuroinflammation and ability to degrade both amyloid and α-synuclein proteins. Notably, two out of three moderate AD patients receiving the highest dose improved to mild-stage AD, maintaining improvement through one year of treatment.
The treatment showed dose-dependent improvements in CSF biomarkers, with 100% of high-dose patients showing improvements in CSF α-synuclein levels after six months, while maintaining stable Aβ42/40 ratio and p-Tau 181 levels.
NKGen Biotech (OTC: NKGN) announced its upcoming presentation at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto, Canada from July 27-31, 2025. The company will present a poster detailing the mechanism of action of troculeucel, their enhanced non-genetically modified NK cell therapy for Alzheimer's disease.
The presentation by Dr. Paul Y. Song will take place on Sunday, July 27, 2025, from 7:30 AM to 4:15 PM ET in the Exhibit Hall. The poster will include Phase I biomarker data and will be available on NKGen's website after the presentation.
NKGen Biotech (OTC: NKGN) has received FDA authorization for an Expanded Access Program (EAP) for troculeucel, its autologous enhanced natural killer cell therapy. The authorization allows treatment of up to 20 patients with various neurodegenerative diseases, expanding beyond their current Phase 2a Alzheimer's trial.
The EAP will include patients with early-stage Alzheimer's, Parkinson's, ALS, Multiple System Atrophy, Progressive Supranuclear Palsy, Frontotemporal Dementia, Corticobasal degeneration, Multiple Sclerosis, and Lewy Body Dementia. Troculeucel has shown preliminary clinical benefits without drug-related adverse events in two Phase I Alzheimer's trials, demonstrating ability to cross the blood-brain barrier and reduce neuroinflammatory markers.
FAQ
What is the current stock price of NKGen Biotech (NKGN)?
What is the market cap of NKGen Biotech (NKGN)?
